ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares traded 4.02% higher at $25.86 on Wall Street last session.
In accordance with the data, 18 analysts cover ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $36.00 and a low of $12.00, we find $25.00. Given the previous closing price of $24.86, this indicates a potential upside of 0.56 percent. ACAD stock price is now 9.62% away from the 50-day moving average and 35.89% away from the 200-day moving average. The market capitalization of the company currently stands at $4.18B.
It has been rated a hold by 9 analysts and a buy by 8. Brokers who have rated the stock have averaged $24.66 as their price target over the next twelve months.
With the price target maintained at $22, Guggenheim recently Upgraded its rating from Neutral to Buy for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD).
In other news, Kihara James, Principal Accounting Officer sold 2,000 shares of the company’s stock on Jun 15. The stock was sold for $48,300 at an average price of $24.15. Upon completion of the transaction, the Principal Accounting Officer now directly owns 9,144 shares in the company, valued at $0.24 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 12, Director Brege Laura sold 4,500 shares of the business’s stock. A total of $111,906 was realized by selling the stock at an average price of $24.87. This leaves the insider owning 13,502 shares of the company worth $0.35 million. Insiders disposed of 91,870 shares of company stock worth roughly $2.38 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ACAD stock. A new stake in ACADIA Pharmaceuticals Inc. shares was purchased by ADAGE CAPITAL PARTNERS GP, L.L.C. during the first quarter worth $31,679,000. WOODLINE PARTNERS LP invested $11,143,000 in shares of ACAD during the first quarter. In the first quarter, HRT FINANCIAL LP acquired a new stake in ACADIA Pharmaceuticals Inc. valued at approximately $6,652,000. SQUAREPOINT OPS LLC acquired a new stake in ACAD for approximately $5,651,000. JUMP FINANCIAL, LLC purchased a new stake in ACAD valued at around $5,092,000 in the second quarter. In total, there are 318 active investors with 94.90% ownership of the company’s stock.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) opened at $25.00 on Wednesday. During the past 12 months, ACADIA Pharmaceuticals Inc. has had a low of $13.73 and a high of $26.04. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.20, and a quick ratio of 2.20. The fifty day moving average price for ACAD is $23.68 and a two-hundred day moving average price translates $19.08 for the stock.
The latest earnings results from ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.27, missing analysts’ expectations of -$0.21 by -0.06. This compares to -$0.70 EPS in the same period last year. The net profit margin was -28.10% and return on equity was -35.70% for ACAD. The company reported revenue of $118.46 million for the quarter, compared to $115.47 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 2.59 percent. For the current quarter, analysts expect ACAD to generate $138.44M in revenue.
ACADIA Pharmaceuticals Inc.(ACAD) Company Profile
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer’s disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. The company was founded in 1993 and is headquartered in San Diego, California.
